10-Q: Xtant Medical Holdings Reports Q3 2024 Results, Revenue Up 12% Year-Over-Year

Xtant Medical Holdings, Inc. announced its third-quarter 2024 results, showing a 12% increase in revenue compared to the same period last year, driven by recent acquisitions.

Summary

• Xtant Medical Holdings reported a net loss of $5.024 million for the third quarter of 2024, compared to a net income of $9.231 million in the same period of 2023.
• The company's total revenue for the third quarter of 2024 was $27.937 million, a 12% increase from $25.019 million in the third quarter of 2023.
• For the nine months ended September 30, 2024, the company's net loss was $13.284 million, compared to a net income of $4.963 million for the same period in 2023.
• The total revenue for the nine months ended September 30, 2024, was $85.754 million, a 36% increase from $63.195 million for the same period in 2023.
• The increase in revenue is primarily attributed to the acquisition of Surgalign Holdings' hardware and biologics business.
• Gross profit margin decreased to 58.4% for the third quarter of 2024 from 61.3% in 2023, but increased to 60.9% for the nine months ended September 30, 2024, compared to 60.7% for the same period in 2023.
• The company's cash and cash equivalents were $6.596 million as of September 30, 2024.
• The company believes its cash and credit facilities will be sufficient to meet its needs through at least November 2025, but may seek additional capital before then.

Sentiment

Score: 5

Explanation: The document presents mixed signals. While revenue growth is strong, the company's net loss and material weaknesses in internal controls are concerning. The licensing agreement and future outlook provide some positive notes, but the overall sentiment is neutral to slightly negative.

Positives

• Revenue growth of 12% in Q3 and 36% for the nine-month period indicates strong sales performance.
• The acquisition of Surgalign Holdings' hardware and biologics business has positively impacted revenue.
• The licensing agreement for SimpliMax provides a significant upfront payment and guaranteed future royalties.
• The company believes it has sufficient liquidity to meet its needs through at least November 2025.

Negatives

• The company reported a net loss of $5.024 million for the third quarter of 2024, a significant decrease from the net income of $9.231 million in the same period of 2023.
• The company reported a net loss of $13.284 million for the nine months ended September 30, 2024, a significant decrease from the net income of $4.963 million for the same period in 2023.
• Gross profit margin decreased in the third quarter of 2024 compared to the same period in 2023.
• The company's disclosure controls and procedures were deemed not effective as of September 30, 2024, due to material weaknesses in internal control over financial reporting.

Risks

• The company may require additional capital before November 2025, and there is no guarantee that it will be able to secure additional funding on acceptable terms.
• The company's disclosure controls and procedures were not effective due to material weaknesses in internal control over financial reporting.
• The company is subject to risks associated with its international operations, including foreign currency exchange rate fluctuations and compliance with foreign legal and regulatory requirements.
• The company is dependent on independent sales agents and distributors, and the loss of key agents could negatively impact revenue.
• The company faces risks related to product liability claims, litigation, and product recalls.
• The company is subject to the effects of inflation and supply chain disruptions, which could result in delayed product launches and higher costs.
• The company is subject to the effects of labor and staffing shortages at hospitals and other medical facilities on the number of elective procedures in which its products are used.

Future Outlook

The company believes its current cash and credit facilities will be sufficient to meet its anticipated cash requirements through at least November 2025, but may seek additional capital before then. The company also expects to receive guaranteed minimum royalties of $3.75 million in 2025 from the SimpliMax licensing agreement.

Management Comments

• Management believes that the company's cash and credit facilities will be sufficient to meet its anticipated cash requirements through at least November 2025.
• Management is continuing to implement measures designed to improve internal control over financial reporting to remediate the identified material weaknesses.

Industry Context

The company operates in the medical technology industry, specifically focusing on orthobiologics and spinal implant systems. The company's growth strategy includes acquisitions, new product launches, and expanding its distribution network, which are common strategies in this industry. The company's performance is affected by factors such as the number of elective procedures, supply chain disruptions, and competition.

Comparison to Industry Standards

• While the document does not provide specific competitor data, the company's revenue growth of 12% in Q3 and 36% for the nine-month period suggests a positive trajectory compared to industry averages, which are typically in the single-digit range for established companies.
• The company's gross profit margin of 58.4% in Q3 and 60.9% for the nine-month period is within the typical range for medical device companies, but the decrease in Q3 indicates potential challenges in production throughput.
• The company's net loss for the quarter and nine-month period is a concern, as many established medical device companies aim for profitability. This suggests that the company is still in a growth phase and is investing heavily in acquisitions and expansion.
• The company's reliance on independent sales agents and distributors is a common practice in the industry, but it also introduces risks related to agent performance and retention.
• The company's focus on acquisitions is a common strategy for growth in the medical device industry, but it also introduces integration risks and potential for goodwill impairment.

Management Changes

Corporate Governance

Legal Proceedings

• The company is subject to potential liabilities under government regulations and various claims and legal actions that are pending or may be asserted from time to time.
• The company has adequately accrued an amount for contingent liabilities currently in existence.

Related Party Transactions

• The company is party to an Investor Rights Agreement, as amended, Registration Rights Agreements and certain other agreements with OrbiMed Royalty Opportunities II, LP and ROS Acquisition Offshore LP, which are funds affiliated with OrbiMed Advisors LLC.
• OrbiMed beneficially owns 52.5% of the company's common stock.
• All related party transactions are reviewed and approved by the Audit Committee or the disinterested members of the full Board of Directors.

Stakeholder Impact

• Shareholders may be concerned about the net loss and material weaknesses in internal controls.
• Employees may be affected by the company's restructuring and cost-cutting measures.
• Customers may be affected by changes in product availability and pricing.
• Suppliers may be affected by changes in the company's purchasing patterns.
• Creditors may be affected by the company's debt levels and ability to repay its obligations.

Next Steps

• The company will continue to implement measures to remediate material weaknesses in internal control over financial reporting.
• The company will focus on integrating acquired businesses and launching new products.
• The company will continue to expand its distribution network and penetrate adjacent markets.
• The company will monitor its cash flow and may seek additional financing if needed.

Key Dates

Keywords

orthobiologics, spinal implants, medical devices, revenue, acquisitions, financial results, net loss, gross profit, liquidity, licensing agreement, internal control, material weakness